TCGA-64-5781-01A-01R-1628-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 55
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- OXIDATIVE_PHOSPHORYLATION+0.510
- ALLOGRAFT_REJECTION+0.460
- INTERFERON_GAMMA_RESPONSE+0.450
- TNFA_SIGNALING_VIA_NFKB+0.430
- INTERFERON_ALPHA_RESPONSE+0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.350
- COAGULATION+0.320
- UV_RESPONSE_UP+0.310
- PEROXISOME+0.290
Top 10 suppressed
- MITOTIC_SPINDLE-0.380
- WNT_BETA_CATENIN_SIGNALING-0.300
- G2M_CHECKPOINT-0.260
- HEDGEHOG_SIGNALING-0.230
- E2F_TARGETS-0.220
- SPERMATOGENESIS-0.100
- NOTCH_SIGNALING-0.060
- UV_RESPONSE_DN-0.060
- ANDROGEN_RESPONSE-0.050
- KRAS_SIGNALING_DN-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 551ADCCD-D116-43D8-AABC-E7E111D79E70 | — | — | 0.898 |
| 2 | C884FB38-DE5C-48BA-95F1-4ABD2991E833 | — | — | 0.866 |
| 3 | 53D8CF8D-31BA-4CB8-A14F-5C9AB9554F5D | — | — | 0.864 |
| 4 | TCGA-D8-A1Y2-01A-11R-A157-07 | — | C | 0.864 |
| 5 | TCGA-64-1676-01A-01R-0946-07 | — | cohortA1 | 0.855 |
| 6 | 65DAB913-D39C-4AC4-BB1C-10E58914571F | — | — | 0.853 |
| 7 | TCGA-35-4122-01A-01R-1107-07 | — | cohortA1 | 0.845 |
| 8 | TCGA-34-5241-01A-01R-1443-07 | — | cohortSQ1 | 0.839 |
| 9 | 31550B35-DA39-4294-8368-811A412B2E3A | — | — | 0.839 |
| 10 | TCGA-05-4418-01A-01R-1206-07 | — | cohortA4 | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.420 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| UV_RESPONSE_UP | 0.310 | Idelalisib | — uncovered |
| PEROXISOME | 0.290 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.290 | Inavolisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.230 | Remibrutinib | — uncovered |